BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 16118805)

  • 1. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
    Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
    Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B.
    Hurd DD; Peters WP
    J Natl Cancer Inst Monogr; 1995; (19):41-4. PubMed ID: 7577204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
    Winer EP; Lindley C; Hardee M; Sawyer WT; Brunatti C; Borstelmann NA; Peters W
    Psychooncology; 1999; 8(2):167-76. PubMed ID: 10335560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
    Shi Y; Pan F; Han X
    Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
    Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208.
    Tokuda Y; Tajima T; Narabayashi M; Takeyama K; Watanabe T; Fukutomi T; Chou T; Sano M; Igarashi T; Sasaki Y; Ogura M; Miura S; Okamoto S; Ogita M; Kasai M; Kobayashi T; Fukuda H; Takashima S; Tobinai K; ;
    Cancer Sci; 2008 Jan; 99(1):145-51. PubMed ID: 17970786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
    Bitran JD; Samuels B; Trujillo Y; Klein L; Schroeder L; Martinec J
    Clin Cancer Res; 1996 Sep; 2(9):1509-13. PubMed ID: 9816327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
    Peters WP; Ross M; Vredenburgh JJ; Meisenberg B; Marks LB; Winer E; Kurtzberg J; Bast RC; Jones R; Shpall E
    J Clin Oncol; 1993 Jun; 11(6):1132-43. PubMed ID: 8501500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer.
    Peters WP; Ross M; Vredenburgh JJ; Hussein A; Rubin P; Dukelow K; Cavanaugh C; Beauvais R; Kasprzak S
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):25-31. PubMed ID: 7916487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
    J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study.
    Toh HC; McAfee SL; Sackstein R; Multani P; Cox BF; Garcia-Carbonero R; Colby C; Spitzer TR
    Bone Marrow Transplant; 2000 Jan; 25(1):19-24. PubMed ID: 10654009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative study on quality of life between weekly and monthly chemotherapy with cisplatin, vindesine and mitomycin C in patients with non-small cell lung cancer].
    Ishihara Y; Ichiwata T; Kuramitsu K; Yoneda S; Yamamoto M; Takizawa T; Ogata T; Uchiyama T; Yoshida K
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1013-20. PubMed ID: 9644316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
    Buijs C; Rodenhuis S; Seynaeve CM; van Hoesel QG; van der Wall E; Smit WJ; Nooij MA; Voest E; Hupperets P; TenVergert EM; van Tinteren H; Willemse PH; Mourits MJ; Aaronson NK; Post WJ; de Vries EG
    J Clin Oncol; 2007 Dec; 25(34):5403-9. PubMed ID: 18048822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast.
    Schwartzberg L; Weaver C; Lewkow L; McAneny B; Zhen B; Birch R; West W; Tauer K; Buckner C
    Bone Marrow Transplant; 1999 Nov; 24(9):981-7. PubMed ID: 10556957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
    Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB
    Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.